NCT05024214 2026-03-25Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors3D MedicinesPhase 1/2 Recruiting170 enrolled
NCT04300556 2026-03-13A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesEisai Inc.Phase 1/2 Recruiting182 enrolled